Imatinib

證據等級: L5

預測適應症: 10 個

Imatinib: From Chronic Myeloid Leukaemia to Heart Fibrosarcoma

One-Sentence Summary

Imatinib is a tyrosine kinase inhibitor originally developed for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). The TxGNN model predicts it may be effective for heart fibrosarcoma, but this direction is currently supported by 0 clinical trials and only 1 non-specific literature review, making it an early-stage research signal rather than an actionable clinical lead.

Quick Overview

Item	Content
Original Indication	Chronic myeloid leukaemia (CML) / gastrointestinal stromal tumour (GIST) — well-established indications for imatinib; no TGA/ARTG-sourced indication text was available in this evidence pack
Predicted New Indication	Heart Fibrosarcoma
TxGNN Prediction Score	99.94%
Evidence Level	L4
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in this evidence pack (data gap DG002, High severity). Based on known information, imatinib is a small-molecule tyrosine kinase inhibitor targeting BCR-ABL, KIT and PDGFR, and its efficacy in CML and GIST is well established; mechanistically, PDGFR-driven signalling is also implicated in a range of fibroblastic/sarcomatous tumours.

The mechanistic link proposed here is an extrapolation from imatinib’s proven activity in dermatofibrosarcoma protuberans (DFSP), a PDGFR-driven fibroblastic tumour, to the broader “fibrosarcoma” disease family in the knowledge graph — of which heart fibrosarcoma is one node. However, heart fibrosarcoma is an extremely rare tumour, and no cardiac-specific data exists: there are no registered clinical trials, and the single supporting publication is a 2008 general review of imatinib’s expanding indications, not a study of cardiac or fibrosarcoma-specific activity.

Because the supporting evidence is mechanistic and generic rather than site-specific, this prediction should be treated as a research hypothesis. Notably, other TxGNN-predicted fibrosarcoma-family indications for imatinib in the same evidence pack (e.g. conventional fibrosarcoma/DFSP, which has a completed Phase 2 trial, and kidney fibrosarcoma, supported by a Phase 2 basket trial) carry stronger evidence and may be more productive avenues to pursue.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18623899	2008	Review	Prescrire International	General review of imatinib’s expanding indications since its original approval for CML/GIST; notes new indications lack robust evidence and does not address heart fibrosarcoma specifically

Australia Market Information

Imatinib currently has 0 ARTG entries and is recorded as not marketed in this evidence pack. No product listing, dosage form, or approved-indication data was available to tabulate.

Cytotoxicity

Imatinib is an antineoplastic agent (tyrosine kinase inhibitor) used across multiple cancer indications, so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (BCR-ABL/KIT/PDGFR tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions — no drug-specific toxicity data was available in this evidence pack
Emetogenicity Classification	Low to moderate (typical for oral tyrosine kinase inhibitors as a class)
Monitoring Items	Full blood count (FBC) with differential, liver function tests, renal function
Handling Protection	Oral antineoplastic agent — follow institutional cytotoxic/hazardous drug handling policy for oral chemotherapy agents

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. Note that TGA-specific warnings and contraindications for imatinib were not retrievable in this evidence pack (data gap DG001, Blocking severity) — this is a prerequisite before any safety assessment (S1 stage) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (heart fibrosarcoma) has no clinical trial evidence and only one non-specific literature reference; combined with imatinib currently being unmarketed in Australia (0 ARTG entries), there is insufficient evidence to justify progressing beyond a research question at this time.

To proceed, the following is needed:

TFDA/TGA Product Information — warnings, contraindications, and DDI data (blocking gap, DG001)
Detailed mechanism of action (MOA) data confirming target expression relevance to heart fibrosarcoma (DG002)
Cardiac/site-specific preclinical or case-level evidence for imatinib activity in fibrosarcoma
Consider evaluating the better-evidenced fibrosarcoma-family predictions in this same evidence pack (conventional fibrosarcoma/DFSP — completed Phase 2 trial; kidney fibrosarcoma — Phase 2 basket trial) as higher-priority candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.